Bristol Myers Squibb’s new $1 billion biologics site in Dublin is officially up and running.
BMS says that the facility, located in Cruiserath, brings the manufacturing capacity needed to meet the growing demand for existing biologic products and support future needs for developing drugs. The 125-acre manufacturing campus, which will employ roughly 450 workers, features a cryogenics logistics facility, as well as space to facilitate commercial testing, released development, and manufacturing of biologics drug substances.
BMS first unveiled plans for the new campus a few years ago, saying then that it was the largest ever capital investment for the company, and its first biologics drug substance facility outside of the U.S. at the time. The site received FDA approval in 2019 and EMA site approval one year later. Now, Cruiserath is ready for commercial manufacture.
According to BMS, the facility will initially manufacture a single product at a time and eventually move to between three to five campaigns per year. The facility is highly flexible and designed to accommodate a variety of cell culture processes.
